Search Results

Mitochon Pharmaceuticals today announced that it was awarded approval from EMA to begin enrollment for a Phase I/IIa biomarker study in Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Huntington’s Disease (HD) and Alzheimer’s Disease (AD) participants.

Mitochon Pharmaceuticals today is pleased to announce the receipt of a $500,000 grant in conjunction with the University of Kentucky for “Advancement of Drugs for the Treatment of Repeated Mild Traumatic Brain Injury (mTBI)” through a joint funded program by an Alzheimer’s Disease group, BrightFocus Foundation and a military focused foundation, Medical Technology Enterprise Consortium (MTEC).

Mitochon Pharmaceuticals today announced that they, in partnership with the University of Kentucky (UK) and Children’s Hospital of Philadelphia (CHOP), were awarded a $3.2M National Institutes of Health grant to study Mitochon’s mitochondrial targeted drug therapies for treating Traumatic Brain Injury (TBI).

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

This important allowance, along with the Company’s open IND will help secure the path forward for the continued clinical development of MP101 in Huntington’s Disease and it further strengthen Mitochon’s exclusivity for MP-101, a repurposed molecule.

Reneo Pharmaceuticals, Inc., a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, reported financial results for the first quarter ended March 31, 2024.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.

The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its pivotal STRIDE study ( NCT04535609 ) of mavodelpar in adult patients with primary

Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.